The ability to get more oxygen to hypoxic (oxygen-starved) tissue provides new treatment opportunities for life-threatening conditions including:

• treatment of solid cancerous tumors in conjunction with radiation therapy
• cardiovascular diseases such as peripheral arterial disease, heart attack and congestive heart failure
• stroke
• respiratory disorders
• other hypoxia-related conditions

The Company’s lead drug, trans sodium crocetinate (TSC), has been shown in animal models to significantly increase the diffusion of oxygen selectively to oxygen-deprived tissue, providing a powerful therapeutic effect.

Studies in animal models also indicate that TSC can be administered, with good bioavailability, intravenously, by intramuscular injection, inhalation, orally, and transdermally, allowing the drug to be adapted to a variety of therapeutic modes targeted at numerous clinical indications, and broadening the development of out-license opportunities.

Other promising drug candidtates in the Company’s proprietary family of molecules have been successfully synthesized and preliminary screening has been conducted with further evaluation and out-license activities pending.